《大行報告》美銀證券:神華(01088.HK)季績遜預期 仍為資源股首選
美銀證券發表報告指,中國神華(01088.HK)公布去年業績預告,按國際會計準則料去年純利為516億元人民幣,較市場及該行預測分別低4%及3%,意味去年第四季純利按季下跌30%,但按年則上升216%至103億元人民幣。
該行表示,神華上季業績遜於投資者預期,因其季度產量按季增長15%至8,280萬噸,基準現貨/年計合約煤價亦按季亦分別按季升18%及17%。公司管理層稱去年第四季業績主要受到生產水平較正常增加,令成本投資同樣上升,及合營電廠虧損擴大等影響。
美銀證券維持中國神華H股「買入」評級及目標價24元,並續為中資資源股首選之一,預期集團今年的成本會回復至正常水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.